LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Fermé

SecteurSoins de santé

31.86 7.16

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

29.78

Max

33.06

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+67.54% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-52M 3B
Ouverture précédente	24.7
Clôture précédente	31.86

Sentiment de l'Actualité

By Acuity

68%

32%

295 / 344 Classement par Healthcare

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 mai 2026, 21:33 UTC

Résultats

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mai 2026, 21:00 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mai 2026, 20:18 UTC

Résultats

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mai 2026, 21:29 UTC

Actions en Tendance

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mai 2026, 21:08 UTC

Résultats

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mai 2026, 21:02 UTC

Résultats

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mai 2026, 20:59 UTC

Acquisitions, Fusions, Rachats

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mai 2026, 20:55 UTC

Résultats

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 mai 2026, 20:48 UTC

Résultats

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mai 2026, 20:45 UTC

Résultats

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mai 2026, 20:34 UTC

Acquisitions, Fusions, Rachats

Webster Financial Stockholders Approve Sale to Banco Santander

27 mai 2026, 20:32 UTC

Résultats

Acquisitions, Fusions, Rachats

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mai 2026, 20:32 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mai 2026, 20:32 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mai 2026, 20:30 UTC

Résultats

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mai 2026, 20:30 UTC

Acquisitions, Fusions, Rachats

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mai 2026, 20:22 UTC

Résultats

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:16 UTC

Résultats

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:13 UTC

Résultats

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mai 2026, 20:13 UTC

Résultats

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mai 2026, 20:13 UTC

Résultats

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mai 2026, 20:12 UTC

Résultats

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mai 2026, 20:12 UTC

Résultats

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

67.54% hausse

Prévisions sur 12 Mois

Moyen 49.91 USD 67.54%

Haut 80 USD

Bas 26 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

295 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.